Here are four notes:
1. The Verasense device provides real-time, quantified soft tissue balance data to help surgeons make objective assessments intraoperatively.
2. Verasense is intended to improve knee balance and implant positioning to prevent premature implant failure and the need for future revision surgery.
3. In a prospective multi-center study, 98 percent of patients whose knees were balanced using Verasense reported being satisfied or very satisfied at three years after surgery.
4. Earlier this year, OrthoSensor won approval to use Verasense with the Persona Knee System in Australia.
“Receiving FDA clearance for Verasense use with the Zimmer Biomet Persona Knee System augments this outstanding implant and instrumentation, securing a better balanced knee after surgery,” said OrthoSensor President and CEO Ivan Delevic.
More articles on supply chain:
Medical device tax causes $34M plunge in R&D funding — 4 notes
Safety alert: Stryker hip replacement devices may break apart
J&J receives $2.8B offer for subsidiary’s sterilization unit — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.